Parkinson's KinetiGraph, PKG in Patients With Deep Brain Stimulation and Continuous Levodopa Infusion Therapy
Parkinson's KinetiGraph, PKG in Patients With Deep Brain Stimulation and Continuous Levodopa Infusion Therapy
In this study the aim is to evaluate the outcome of deep brain stimulation (DBS) and
 continuous intraduodenal levodopa therapy in patients with advanced Parkinson' disease by
 using Parkinson's KinetiGraph™ device which is a movement and acceleration measuring device.
 In this study we also evaluate the usability of Parkinson's KinetiGraph™ device by comparing
 it with written patient diaries.
In this study the aim is to evaluate the outcome of deep brain stimulation (DBS) and
 continuous intraduodenal levodopa therapy in patients with advanced Parkinson' disease by
 using Parkinson's KinetiGraph™ logger (PKG) device which is a movement and acceleration
 measuring device.

 A measurement is done before and after the implantation of selected therapy. PKG will measure
 automatically in every two minutes the movement of selected limb (usually the more affected
 upper extremity) for six days. At the same time a patient will keep a written diary of
 his/her Parkinsonian symptoms. Diary and collected PKG data will be compared. PKG will also
 remind with vibration the patient of the time drug administration and the patient can confirm
 this with pressing a button on PKG. The collected data will be transmitted to a computer and
 analyzed mathematically to produce a visual graph of daily movements. The aim is to evaluate
 PKG's usability in measuring Parkinsonian symptoms and in evaluation the outcome of DBS and
 levodopa therapy. Main parameters in evaluation are bradykinesia score and dyskinesia score.
Inclusion Criteria:

 -  Patient with diagnosed Parkinson's disease

 -  Parkinson's disease is in advanced state (defined by the treating physician)

 -  A good response with over 30 % improvement of scores in Unified Parkinson's disease
 rating scale part III in pre-DBS evaluation

 Exclusion Criteria:

 -  Age older than 70 years (this is a clinical exclusion criteria for DBS treatment)

 -  No history of psychosis or depression (this is a clinical exclusion criteria for DBS
 and intraduodenal levodopa therapy)

 -  No diagnosed dementia (this is a clinical exclusion criteria for DBS and intraduodenal
 levodopa therapy)